Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the Tumor Myeloid-Directed Therapies Summit Annual Meeting
May 23 2022 - 7:30AM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB)
(“Navidea” or the “Company”), a company focused on the development
of precision immunodiagnostic agents and immunotherapeutics, today
announced acceptance of its abstract titled, “CD206 Targeted
Delivery of Bisphosphonate Payloads Alter Human Macrophage
Phenotypes Towards M1-like” for presentation of a poster at this
year’s Tumor Myeloid-Directed Therapies Summit.
The 2nd annual Tumor Myeloid-Directed Therapies Summit meeting
will be held June 14-16, 2022 in Boston, MA. The presentation will
take place Tuesday, June 14. Meeting information can be found on
the conference website
(https://tumor-myeloid-therapeutics.com).
The poster will present information related to the synthesis of
two novel bisphosphonate drugs that have been attached to Navidea’s
CD206-targeted drug delivery platform molecule, Manocept. These
constructs use a novel degradable linker to release the therapy
only once they have been internalized into a CD206-expressing cell,
such as a tumor associated macrophage. The new therapeutic
constructs were evaluated in human macrophage cell culture assays
to compare the ability of the new constructs with unbound free
therapy to shift the phenotype of macrophages toward a
proinflammatory gene expression pattern. The new drug delivery
constructs successfully shifted the phenotypes of human macrophages
towards a proinflammatory state and compared favorably to the
unbound free therapy. The new drug constructs also induced a highly
significant reduction in macrophage expression of signal regulatory
protein alpha (“SIRPα”), the receptor for the “don’t eat me” signal
that, when activated, suppresses the ability of macrophages to
attack and phagocytize disease associated cells such as cancer
cells. The ability to induce this type of phenotypic change in
macrophages could have far-reaching applications in cancer
immunotherapy.
Dr. Michael Rosol, Chief Medical Officer for Navidea, said,
“These new therapeutic constructs demonstrate the power of our
adaptable platform technology to deliver a wide array of small
molecule payloads in a targeted fashion to macrophages involved in
the propagation of a variety of severe illnesses including
cancer.”
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
Forward-looking statements include our expectations regarding
pending litigation and other matters. These forward-looking
statements are subject to a number of risks, uncertainties and
assumptions, including, among other things: our history of
operating losses and ability to obtain additional financing; our
ability to continue as a going concern; the final outcome of any
pending litigation; our ability to successfully complete research
and further development of our drug candidates; the timing, cost
and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; dependence on royalties and grant revenue; our ability
to implement our growth strategy; anticipated trends in our
business; our limited product line and distribution channels;
advances in technologies and development of new competitive
products; our ability to comply with the NYSE American continued
listing standards; our ability to maintain effective internal
control over financial reporting; the impact of the current
coronavirus pandemic; and other risk factors detailed in our most
recent Annual Report on Form 10-K and other SEC filings. You are
urged to carefully review and consider the disclosures found in our
SEC filings, which are available at http://www.sec.gov or at
http://ir.navidea.com.
Investors are urged to consider statements that include the
words “will,” “may,” “could,” “should,” “plan,” “continue,”
“designed,” “goal,” “forecast,” “future,” “believe,” “intend,”
“expect,” “anticipate,” “estimate,” “project,” and similar
expressions, as well as the negatives of those words or other
comparable words, to be uncertain forward-looking statements.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report
may not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220523005345/en/
Investor Relations Contact Navidea Biopharmaceuticals,
Inc. Jeffrey Smith Vice President of Operations 614-822-2365
jsmith@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024